219553-50-1

Basic information

• Product Name: 1-N-(tert-butoxycarbonyl)-3-<4-(2-cyanoethoxycarbonyl)-4-phenylpiperidin-1-yl>propylamine
• Synonyms: 1-N-(tert-butoxycarbonyl)-3-<4-(2-cyanoethoxycarbonyl)-4-phenylpiperidin-1-yl>propylamine
• CAS NO: 219553-50-1
• Molecular Weight: 415.533
• Mol File: 219553-50-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-N-(tert-butoxycarbonyl)-3-<4-(2-cyanoethoxycarbonyl)-4-phenylpiperidin-1-yl>propylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-(tert-butoxycarbonyl)-3-<4-(2-cyanoethoxycarbonyl)-4-phenylpiperidin-1-yl>propylamine(219553-50-1)
• EPA Substance Registry System: 1-N-(tert-butoxycarbonyl)-3-<4-(2-cyanoethoxycarbonyl)-4-phenylpiperidin-1-yl>propylamine(219553-50-1)

Safety Data

• Hazardous Substances Data: 219553-50-1(Hazardous Substances Data)

Upstream product

• 166810-76-0 3-(4-Ethoxycarbonyl-4-phenylpiperidin-1-yl)-propylamine 
• 219553-42-1 1-(3-aminopropyl)-4-phenylpiperidine-4-carboxylic acid 
• 77-17-8 Normeperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 109-78-4 3-Hydroxypropionitrile 
• 219553-44-3 1-<3-(N-tert-butoxycarbonylamino)propyl>-4-phenylpiperidine-4-carboxylic acid 

Downstream Products

• 166808-42-0 5-carboxamido-1,4-dihydro-2,6-dimethyl-3-carboxamido>-4-(4-nitrophenyl)pyridine 
• 166808-43-1 5-carboxamido-3-carboxamido>-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine 
• 219553-51-2 3-<4-(2-cyanoethoxycarbonyl)-4-phenylpiperidin-1-yl>propylamine 

Relevant articles and documents

Design and synthesis of novel α1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia

We report the synthesis and evaluation of novel ttia adrenoceptor subtype-selective antagonists. Systematic modification of the lipophilic 4,4-diphenylpiperidinyl moiety of the dihydropyridine derivatives 1 and 2 provided several highly selective and potent α1a antagonists. From this series, we identified the 4-(methoxycarbonyl)-4-phenylpiperidine analogue SNAP 5540 (-) [(-)-63] for further characterization. When examined in an isolated human prostate tissue assay, this compound was found to have a Ki of 2.8 nM, in agreement with the cloned human receptor binding data (Ki = 2.42 nM). Further evaluation of the compound in isolated dog prostate tissue showed a Ki of 3.6 nM and confirmed it to be a potent antagonist (Kb = 1.6 nM). In vivo, this compound effectively blocked the phenylephrine-stimulated increase in intraurethral pressure (IUP) in mongrel dogs, at doses which did not significantly affect the arterial pressure (diastolic blood pressure, DBF), with a DBF Kb/IUP-Kb ratio of 16. In addition, (-)-63 also showed greater than 40 000-fold selectivity over the rat L-type calcium channel and 200-fold selectivity over several G protein-coupled receptors, including histamine and serotonin subtypes. These findings prove that aia adrenoceptor-subtype selective antagonists such as (-)-63 may be developed as uroselective agents for an improved treatment of BPH over nonselective 0.1 antagonists such as prazosin and terazosin, with fewer side effects.